相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study
Jun Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Y. Doki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Wenwu He et al.
ONCOLOGIST (2022)
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang et al.
CANCER CELL (2022)
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Mojun Zhu et al.
CLINICAL CANCER RESEARCH (2022)
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer
Sarah M. H. Einerhand et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
Xiaolong Yan et al.
INTERNATIONAL JOURNAL OF SURGERY (2022)
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lu et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
Hongtao Duan et al.
FRONTIERS IN IMMUNOLOGY (2022)
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Jun Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)
Lei Gao et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2022)
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S. Loibl et al.
ANNALS OF ONCOLOGY (2022)
Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis
Zhaoyang Wang et al.
INTERNATIONAL JOURNAL OF SURGERY (2022)
Effects of Radiotherapy on Survival of Esophageal Cancer Patients Receiving Immunotherapy Propensity Score Analysis and Nomogram Construction
Yuanliu Nie et al.
CANCER MANAGEMENT AND RESEARCH (2022)
Enhancing anti-tumour efficacy with immunotherapy combinations
Funda Meric-Bernstam et al.
LANCET (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Tom van den Ende et al.
CLINICAL CANCER RESEARCH (2021)
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Chengqiang Li et al.
EUROPEAN JOURNAL OF CANCER (2021)
Paradigms on Immunotherapy Combinations with Chemotherapy
Diego Salas-Benito et al.
CANCER DISCOVERY (2021)
Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
Peng Yang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)
The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
Dijian Shen et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study
Wenqun Xing et al.
FRONTIERS IN IMMUNOLOGY (2021)
A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)
Hongtao Duan et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)
Zhenyang Zhang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
Annette M. Lim et al.
FRONTIERS IN ONCOLOGY (2021)
Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
W. Yao et al.
ESMO OPEN (2021)
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Jose Carlos Benitez et al.
CLINICAL CANCER RESEARCH (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Clinical Challenges of Immune Checkpoint Inhibitors
Maria de Miguel et al.
CANCER CELL (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment after progression in the era of immunotherapy
Salem Billan et al.
LANCET ONCOLOGY (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
Taisuke Yagi et al.
ANNALS OF SURGERY (2019)
Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.
Ronan Joseph Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Jing Lio et al.
ONCOIMMUNOLOGY (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
Jake S. O'Donnell et al.
CLINICAL CANCER RESEARCH (2019)
Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
Nataliya Volodymyrivna Uboha et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).
Min Hee Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma
Eiji Fukuoka et al.
ANTICANCER RESEARCH (2019)
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence
Max Lacour et al.
CLINICAL LUNG CANCER (2019)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A. Rozeman et al.
LANCET ONCOLOGY (2019)
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Peng Liu et al.
NATURE COMMUNICATIONS (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
Eric Deutsch et al.
LANCET ONCOLOGY (2019)
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
So-Jin Park et al.
ORAL ONCOLOGY (2019)
Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy
Xiu-Yong Liao et al.
ONCOLOGY LETTERS (2019)
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Ludovic Fournel et al.
CANCER LETTERS (2019)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles et al.
NATURE MEDICINE (2019)
Intratumoral CD8+T cells with stem cell-like properties: Implications for cancer immunotherapy
Werner Held et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
Wan-Ting Huang et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Caroline S. Jansen et al.
NATURE (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T. R. Cottrell et al.
ANNALS OF ONCOLOGY (2018)
Epidemiology of Esophageal Squamous Cell Carcinoma
Christian C. Abnet et al.
GASTROENTEROLOGY (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Safety of combining radiotherapy with immune-checkpoint inhibition
William L. Hwang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse
Stephen Mok et al.
CANCER RESEARCH (2018)
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study-NADIM study-SLCG.
Mariano Provencio-Pulla et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
Hong Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun et al.
LANCET ONCOLOGY (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018)
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Is earlier better for melanoma checkpoint blockade?
Caroline Robert
NATURE MEDICINE (2018)
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Yixin Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
Charlotte Leduc et al.
ESMO OPEN (2018)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor
Wencheng Zhang et al.
CANCER SCIENCE (2017)
Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model
Yanhong Wu et al.
BMC IMMUNOLOGY (2016)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
The immune mechanisms of abscopal effect in radiation therapy
G. Daniel Grass et al.
CURRENT PROBLEMS IN CANCER (2016)
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Genta Sawada et al.
GASTROENTEROLOGY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression
Miao-Fen Chen et al.
ONCOTARGET (2016)
Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis
Hai-Xia Qu et al.
JOURNAL OF THORACIC DISEASE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
Ling Zhang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2015)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
Kobe Reynders et al.
CANCER TREATMENT REVIEWS (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Identification of genomic alterations in oesophageal squamous cell cancer
Yongmei Song et al.
NATURE (2014)
Genetic landscape of esophageal squamous cell carcinoma
Yi-Bo Gao et al.
NATURE GENETICS (2014)
Genomic and molecular characterization of esophageal squamous cell carcinoma
De-Chen Lin et al.
NATURE GENETICS (2014)
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
Elena Garcia-Martinez et al.
BREAST CANCER RESEARCH (2014)
Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells
Hiromi Sakai et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Esophageal carcinoma advances in treatment results for locally advanced disease: review
A. Herskovic et al.
ANNALS OF ONCOLOGY (2012)
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Anurag Gupta et al.
JOURNAL OF IMMUNOLOGY (2012)
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
Apar Pataer et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cytokines in Radiobiological Responses: A Review
Doerthe Schaue et al.
RADIATION RESEARCH (2012)
Role of T lymphocytes in tumor response to radiotherapy
Sandra Demaria et al.
FRONTIERS IN ONCOLOGY (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)